Skip to main content

Table 1 Follow-up schedule of examination

From: Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

  Baseline 1 month 2 months 3 months Every 1 month Every 3 months Discontinuation of therapy
Informed consent       
Medical history       
Confirmation of eligibility criteria       
Randomization       
Serum testosterone       
FACT-P
PSAa
Biochemical examinationa
CT, bone scintigraphy When progressive disease is suspectedb
Safety
Further therapy Best standard care
  1. aAfter the discontinuation of enzalutamide or flutamide, PSA and biochemical examination will be continued until September 2018
  2. bWhen progressive disease is suspected, CT and bone scintigraphy will be performed to confirm radiographic disease progression